Valsecchi Nicola, Hasan Nasiq, Sadeghi Elham, Chhablani Jay
Department of Ophthalmology, University of Pittsburgh, School of Medicine, Pittsburgh, PA, USA.
Ophthalmology Unit, Dipartimento Di Scienze Mediche E Chirurgiche, Alma Mater Studiorum University of Bologna, Bologna, Italy.
Graefes Arch Clin Exp Ophthalmol. 2025 Feb 11. doi: 10.1007/s00417-025-06766-0.
To assess the effects of oscillatory photodynamic therapy (OPDT) with verteporfin in patients with chronic central serous chorioretinopathy (cCSCR).
Retrospective study including eyes with cCSCR who underwent OPDT by a single retina specialist. Best-corrected visual acuity (BCVA), central macular thickness (CMT), subfoveal choroidal thickness (SFCT), and subretinal fluid (SRF) height were assessed before and after OPDT. Full dose verteporfin was administered with half-fluence protocol. During the procedure, the laser beam was oscillated at 2-3 Hertz with the lens steady, treating areas with hyperpermeability on indocyanine green angiography (ICGA). Linear mixed models were used to compare BCVA, CMT, SRF height, and SFCT before and after treatment.
A total of 28 eyes of 20 patients were included, mean age was 52.71 ± 13.22, and 4 were females (20%). OPDT involving the fovea was performed in 46.42% of the cases. After a mean of 12.57 ± 8.10 months, complete resolution of SRF was observed in 89.28% of eyes, with a full resolution after the first OPDT in 78.57%. Overall, BCVA improved from 0.21 ± 0.17 to 0.11 ± 0.11 logMar (p = 0.003), and CMT, SFCT, and SRF height showed a significant decrease at the last follow-up assessment (p = 0.007; p = 0.001; and p = 0.002 respectively). BCVA was similar in eyes treated with extra-foveal and foveal OPDT (p = 0.963). No major complications were observed at 12-month follow-up.
OPDT including foveal application is a safe and effective treatment in cCSCR, with complete resolution of SRF in almost 90% of cases with minimal changes or recurrence.
评估使用维替泊芬的振荡光动力疗法（OPDT）对慢性中心性浆液性脉络膜视网膜病变（cCSCR）患者的疗效。
一项回顾性研究，纳入由一名视网膜专科医生进行OPDT治疗的cCSCR患者的眼睛。在OPDT前后评估最佳矫正视力（BCVA）、中心黄斑厚度（CMT）、黄斑中心凹下脉络膜厚度（SFCT）和视网膜下液（SRF）高度。采用半剂量方案给予全剂量维替泊芬。在治疗过程中，激光束以2 - 3赫兹振荡，晶状体保持稳定，对吲哚菁绿血管造影（ICGA）显示有高渗透性的区域进行治疗。使用线性混合模型比较治疗前后的BCVA、CMT、SRF高度和SFCT。
共纳入20例患者的28只眼睛，平均年龄为52.71±13.22岁，女性4例（20%）。46.42%的病例进行了累及黄斑中心凹的OPDT。平均12.57±8.10个月后，89.28%的眼睛SRF完全消退，78.57%的眼睛在首次OPDT后完全消退。总体而言，BCVA从0.21±0.17提高到0.11±0.1 logMar（p = 0.003），在最后一次随访评估时，CMT、SFCT和SRF高度均显著降低（分别为p = 0.007；p = 0.001；p = 0.002）。黄斑中心凹外和黄斑中心凹OPDT治疗的眼睛BCVA相似（p = 0.9
